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Background: We report clinical and molecular cytogenetic characterization of a 2 year-old girl with 19p13.2p13.12
microdeletion and compare her clinical features with those of three other patients reported before.
Result: Array comparative genomic hybridization (aCGH) revealed in the present patient a de novo microdeletion
of 1.45 Mb within 19p13.2p13.12. The deletion includes seven OMIM genes: MAN2B1, RNASEH2A, KLF1, GCDH, NFIX,
CACNA1A and CC2D1A.
Discussion: The present case and three other patients with partially overlapping 19p13 microdeletion share the
following features: psychomotor and language delay, intellectual disability, seizures, hypotonia, skeletal anomalies
and facial dysmorphism. The smallest region of overlapping between all four reported patients is around
300 kb and spans only two genes: NFIX and CACNA1A. Their haploinsufficincy could be the base for the
phenotype -genotype correlation.
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Array comparative genomic hybridization (aCGH) has
allowed for identification of the underlying molecular
bases for numerous patients with multiple congenital
anomalies. De novo microdeletion 19p13 detected by
aCGH is rarely reported [1-4]. However, all yet known
patients had intellectual disability and multiple con-
genital anomalies.
We report clinical and molecular cytogenetic
characterization of a 2 year-old girl with a 19p13.2 to
19p13.12 microdeletion and compare her clinical fea-
tures with those of three other patients [1,2,4]. The
phenotype is mainly characterized by psychomotor and
language delay, intellectual disability, seizures, hypo-
tonia, skeletal anomalies and facial dysmorphism. The
shortest region of overlap (SRO) extending for about* Correspondence: abdelnat@yahoo.fr
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unless otherwise stated.300 Kb between the four cases contains candidate genes
responsible for their common phenotype (severe devel-
opmental delay, seizures, and skeletal anomalies). This
microdeletion encompasses seven OMIM genes, among
which two (NFIX and CACNA1A) could be the candi-
date genes for the genotype-phenotype relationship.Case presentation
Case report
The female patient was born at 36 weeks of gestational
age to Moroccan consanguineous parents (first degree)
with non-contributive familial history. She was referred
to genetic consultation for suspicion of Angelman syn-
drome. She is the fifth liveborn to a 44-year-old mother
and 55-year-old father. The mother was followed for
chronic myeloid leukemia and was taking Imatinib dur-
ing her pregnancy (400 mg/day). Still, pregnancy was
without reported complications. Birth weight and lengthtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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centile), head circumference was 31 cm (50th percent-
ile). She had neonatal hypotonia and seizures since her
birth. At clinical examination at fifteen months of age,
her weight was 12 kg (>95th centile), and her head cir-
cumference 52 cm (>95th centile). She had severe axial
hypotonia and was unable to hold her head or sit down
in addition to absent speech. She also had facial dys-
morphism including frontal bossing, down slanting palpe-
bral fissures, microstomia, long philtrum, prognathia,
anteverted nostrils, low-set ears, short neck (Figure 1) and
also bilateral clinodactyly of the fifth finger.
At 2 years and 3 months her length was 97 cm
(>95th centile), weight 15 kg (95th centile), and head
circumference 52 cm (>95th centile). She was still
hypotonic, unable to hold her head or to sit down, and
with absent speech. The cerebral MRI showed bilateral
frontal cortical atrophy. The EEG showed epileptiform
focal abnormalities disorganized background rythm of
slow (2-3 Hz) waves.
Methods
Peripheral blood was collected from the patient and her
parents. Informed consent was obtained from the patient’s
parents prior to implementation of the genetic studies.
Cytogenetics analysis
Cytogenetics studies were performed on metaphase
chromosome preparations obtained from phytohem-
agglutinin stimulated lymphocyte cultures according
to standard procedures. Chromosome analysis was car-
ried applying RHG banding at a 400-band level as pre-
viously reported and according to the International
System for Human Cytogenetic: Nomenclature ISCN
2013 [5,6].Figure 1 Photographs of the patient at age of 2 years and 3 months,
nares, thin upper lip, anteverted ears and long philtrum.DNA samples
DNA was extracted from whole blood using the QIAmp
DNA Kit (QIAGEN) according to the manufacturer’s
instructions.
Methyl PCR
Methyl PCR was performed with Epitect Bisulfite Kit
and EpiTect MSP kit according to the manufacturer’s in-
structions (QIAGEN).
Array-based comparative genomic hybridization
aCGH was carried out using 180 K-oligonucleotide array
(Agilent, San Clara, CA) with an average resolution of
about 25 kb, the procedure for DNA digestion and
hybridization were performed according to the manufac-
turer’s instruction. For analysis of the result two databases
were used respectively for the chromosomal localization:
UCSC genome browser (http://genome.UCSC.edu) and
for polymorphism control: database of genomic variants
(http://dgv.tcag.ca/).
Fluorescent in-situ hybridization (FISH) analysis
FISH was performed on PHA-stimulated peripheral
blood lymphocytes obtained from patient and both par-
ents. BAC RP11-782D11 (located in 19p13.2p13.13) and
CTD-2265021 (19q subtelomeric) probes obtained from
CHORI (Oakland, CA) were used according standard
protocols.
Results
The karyotype was normal and presence of Angelman
syndrome was excluded by methylation specific PCR
(MSPCR) (data not shown). In the absence of any etio-
logical diagnosis, array-CGH analysis identified a
1.45 Mb deletion at 19p13.2p13.12 in the patientfrontal (a) and lateral (b) view. Note the tall forehead, anteverted
Figure 2 aCGH result shows the extend of the 19p13.2p13.12 deletion in the patient, with breakpoints at genomic positions 12,691,
241-14,141,544 (GRCHh37/hg19).
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14,141,544)x1, GRCHh37/hg19. The deleted region in-
cluded 44 genes. Except for polymorphic regions, no
copy number alterations were observed in other chromo-
somes. Because of the necessity to compare with other
cases we reanalyzed with the hg 18 Build 36 version and
the breakpoints were: 12,552,241-14,002,544. (NCBI36/
hg18) The deletion was confirmed by FISH analysis
(Figure 3), and is considered to be do novo since nei-
ther parent carries the deletion (data not shown). We
report here, a 1.45 Mb microdeletion 19p13.2p13.12 in
a child with overgrowth and multiple congenital anom-
alies. This deletion encompasses 44 genes from which only
seven (MAN2B1,RNASEH2A, KLF1, GCDH, NFIX, CAC-
NA1A, and CC2D1A) were OMIM genes and reportedly
as involved in human diseases.
Conclusion
Microdeletion 19p13 has been rarely reported in the
literature [1-4]. This region has a high gene density
and this is most likely the reason why deletions in this
region are associated with a severe phenotype. Actu-
ally with the development of the chromosomal micro-
array analysis technology there has been a little
increase in the number of reported cases with a micro-
deletion 19p13 [4]. The clinical features common toFigure 3 FISH analysis of the 19p13.2-p13.12 deletion. Spectrum-orang
subtelomeric (CTD-2265021) probe (Tel 19q) used for identification of chro
chromosome del(19)(p13.2 ~ 13.12p13.2 ~ 13.12).our patient and the cases reported before [1,2,4] are
psychomotor and language delay, intellectual disabil-
ity, seizures, hypotonia, skeletal anomalies and facial
dysmorphism (Table 1).
The four cases share approximately a 300-kb shortest
region of overlap (SRO) including NFIX1 and CAC-
NA1A genes (Figure 4). This region had never been de-
scribed as a copy number polymorphism (CNP) in the
database of genomic variants (http://dgv.tcag.ca). NFIX
[Nuclear Factor IX (CCAAT-binding transcription fac-
tor)] (OMIM 164005), a member of the nuclear factor I
(Nfi) family of transcription factors, is highly expressed
in the developing mouse brain and an essential gene
for normal brain and skeletal development [5,7]. NFIX
deficient mice show enlargement of the lateral and
third brain ventricles and partial agenesis of the corpus
callosum [7,8]. Our patient and the case of Auvin et al.
[2] showed advanced bone age. Lysy et al. [1] reported
craniosynostosis and kyphosis in their patients. The
phenotype associated with NFIX haploinsufficiency
may occur with variable penetrance because the third
case reported by Bonaglia et al. [4] does not show any
of these malformations. Other study demonstrates that
NFIX deletion and its nonsense mutation (c.179T_C
(p.Leu60Pro) and c.362G_C (p.Arg121Pro)) are associ-
ated with a novel clinically recognizable overgrowthe labeled BAC clone RP11-782D11 and spectrum-green labeled 19q
mosomes 19. Arrow indicate the absence of orange signal on
Table 1 Summary of clinical features and cytogenetic characteristics of the reported patients with 19p13 deletion overlapping with our patient
Patient Present patient Bonaglia et al. [4] Patient 3 Auvin et al. [2] Lysy et al. [1] Clinical score
Gender Female Male Male Female
Chrom.region 19p13.2-p13.12 19p13.13-p13.12 19p13.13 19p13.2-p13.13
Deletion size Mb 1.45 Mb 1.5 Mb 664 Kb 3 Mb
Position (hg18) 12.55-14.00 12.87-14.15 12.61-13.28 10.25-13.18
At birth
Weight < 3rd < 3rd Normal −2SD
Length < 3rd < 3rd Normal −2SD
OFC 50th 10-15th Normal −2SD
At last evaluation
Age 23/12 years 7 years 2 years 38/12 years
Weight >95 th 50th +2SD −2SD
Length 95 th 75th +3SD −2SD
OFC 95 th 50th +2,5SD −2SD
Clinical features
Hypotonia Severe + + + 4/4
Psychomotor delay + Moderate- severe + + 4/4
Language delay + + + + 4/4
Seizure/EEG anomalies + + + + 4/4
Hearing loss - Bilateral conductive - Bilateral threshold 60 dB 2/4
Skeletal Advanced bone age Scoliosis Advanced bone age Craniocynostosis with left
spleno-orbital dysplasia
4/4




Brachycephaly + + - - 2/4
Philtrum long long - - 2/4
Nose Anteverted nares Anteverted nares Flat - 3/4

















Figure 4 Schematic representation of 19p13.2-p13.12 region deleted in our patient and three other reported in the literature sharing
about 300 kb indicated by color rectangle.
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drome [8,9]. The CACNA1A gene (calcium channel
alpha 1A subunit) (OMIM 601011) is involved with the
voltage–dependant Ca 2+ channels and has been re-
ported in association with epilepsy and chronic neuro-
logical disorders, haploinsufficiency of this gene has
been suggested to be responsible for epilepsy and in-
fantile spasms [10,11]. Recently Marangi et al. report a
deletion 19p12.13-p13.13 encompassing the first exon
of the CACNA1A in a patient with EEG focal anomal-
ies and suffering from febrile seizures [12]. In addition
CACNA1A gene has been involved in the occurrence
of developmental delay [13,14]. We suggest that CAC-
NA1A gene deletion is likely responsible for the epilep-
tic seizures in our patient.
In addition through this case report, we want to focus
on the importance of a (aCGH) as a first-tier diagnostic
step for patients with developmental disabilities and/or
multiples congenital anomalies as reported by several
scientific papers [15-18].
This report gives more information for the recently
identified 19p13 deletion syndrome and clarifies the
clinical implication of genes in the involved chromo-
somal region. Also, our paper may contribute to a better
understanding of the genotype-phenotype correlation in
cases with deletion in 19p13 and particularly in the in-
volvement of NFIX and CACNA1A genes in overgrowth,
epilepsies and developmental delay.Consent
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